MIR16-1 and cancer: Another informal confirmation of the validity of the CMC scoring system may be the fact that all miRNA genes whose miRNAs have been tested in clinical trials of cancer therapies either as anti-cancer drugs (miRNA mimics, i.e. MIR16-1, MIR34A and MIR193A) or targets for miRNA inhibitors (antagomiRs; i.e. MIR155 and MIR10B) (96) are included in the CMC, mainly with very high CMC scores (Figure 2, Supplementary Table S9).